Radiotherapy and cellular signalling

Lancet Oncology

Volumn 2, Issue 6, 2001, Pages 366-370

  Lewanski, Conrad R ^a   Gullick, William J ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH PROMOTOR;

ATAXIA TELANGIECTASIA; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; ONCOGENE RAS; RADIATION EXPOSURE; RADIOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ATAXIA TELANGIECTASIA; GENE THERAPY; GENES, P53; GENES, RAS; GROWTH SUBSTANCES; HUMANS; NEOPLASMS; RADIOTHERAPY; SIGNAL TRANSDUCTION;

EID: 0035382714     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00391-0     Document Type: Review

References (33)

1. Hallahan D., Dunphy E., Virudachalam S., et al. c-Jun and Egr-1 participate in DNA synthesis and cell survival in response to ionising radiation exposure. J Biol Chem. 268:1993;1903-1907.
2. Haimovitz-Friedman A., Kan C.-C., Ehleiter D., et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 180:1994;525-535.
3. Santana P., Pena L., Haimovitz-Friedman A., et al. Acid-sphingomyelinase deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 86:1996;189-199.
4. Haimovitz-Friedman A. Radiation-induced signal transduction and stress response. Radiat Res. 150:1998;S102-108.
5. Meyn M., Srasfeld L., Allen C. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia telangiectasia. Int J Radiat Biol. 66:1994;S141-149.
6. Liao W.C., Haimovitz-Friedman A., Persaud R., et al. ATM gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem. 274:1999;17908-17917.
7. Enns L., Barley R., Paterson M., et al. Radiosensitivity in ataxia telangiectasia fibroblasts is not associated with deregulated apoptosis. Radiat Res. 150:1998;11-16.
8. Slichenmyer W., Nelson W., Slebos R., et al. Loss of a p53 associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:1993;4164-4168.
9. McIlwrath A., Vasey P., Ross G., et al. Cell cycle arrest and radiosensitivity of human tumour cell lines; dependence on wild-type P53 for radiosensitivity. Cancer Res. 54:1994;3718-3722.
10. Komorov P., Komorova E., Kondratov R., et al. A chemical inhibitor of P53 that protects mice from the side effects of cancer therapy. Science. 285:1999;1733-1737.
11. Sklar M. The RAS oncogenes increase the intrinsic radioresistance of NIH 3T3 cells to ionizing radiation. Science. 239:1988;645-647.
12. Cohen-Johnathan E., Toulas C., Ader I., et al. The farnesyltransferase inhibitor FTI-277 suppresses the 24 kDa FGF2-induced lines with activating mutations of RAS oncogenes. Cancer Res. 58:1998;1754-1761.
13. Bernhard E., McKenna W., Hamilton A., et al. Inhibiting RAS prenylation increases the radiosensitivity of human tumour cell lines with activating mutations of RAS oncogenes. Cancer Res. 58:1998;1754-1761.
14. Soldatenkov V., Dritschilo A., Wang F., et al. Inhibition of RAF1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. Cancer J Sci Am. 3:1997;13-20.
15. Gokhale P., McRae D., Monia B., et al. Antisense RAF oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucl Acid Drug Dev. 9:1999;191-201.
16. Gullick W.J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 47:1991;87-98.
17. Peter R., Beetz A., Ried C., et al. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res. 136:1993;65-70.
18. Reardon D., Contessa J., Mikkelsen R., et al. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene. 18:1999;4756-4766.
19. Schmidt-Ulrich R., Mikkelsen R., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 15:1997;1191-1197.
20. Huang S., Bock J., Harari P. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
21. Bonner J, Ezekiel M, Robert F, et al. Continued response following treatment with IMC-C225, an EGFr MOAb, combined with RT in advanced head and neck malignancies. Proc Am Soc Clin Oncol 2000; 19: Abstr 5F.
22. Huang P., Harari P. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumour angiogenesis. Clin Cancer Res. 6:2000;2166-2174.
23. Gusterson B., Gelber R., Goldhirsch A., et al. Prognostic importance of c-ERBB-2 expression in breast cancer. J Clin Oncol. 10:1992;1049-1059.
24. Pietras R., Poen J., Gallardo D., et al. Monoclonal antibody to HER2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59:1999;1347-1355.
25. Thomas K. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 271:1996;603-606.
26. Gorski D., Beckett M., Jaskowiak N., et al. Blockade of vascular endothelial growth factor stress response increases the antitumour effects of ionizing radiation. Cancer Res. 59:1999;3374-3378.
27. Fuks Z., Persaud R., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 54:1994;2582-2590.
28. Verheij M., Blitterswijk W., Bartelink H. Radiation-induced apoptosis. The ceramide-SAPK signalling pathway and clinical aspects. Acta Oncol. 37:1998;575-581.
29. Carter S., Auer K., Reardon D., et al. Inhibition of MAP kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene. 16:1998;2787-2796.
30. Martin M., Lefaix J., Delanian S. TGFβ and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys. 47:2000;277-290.
31. Delanian S., Baillet F., Huart J., et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol. 32:1994;12-20.
32. Hallahan D., Vokes E., Rubin S., et al. Phase I dose-escalation study of tumour necrosis factor α and concomitant radiation therapy. Cancer J Sci Am. 1:1995;204.
33. Hallahan D., Mauceri H., Seung L., et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1:1995;786-791.